Disease progression of alpha-mannosidosis and impact on patients and carers – a UK natural history survey

Show simple item record

dc.contributor.author Adam, Jacqueline
dc.contributor.author Malone, Rachel
dc.contributor.author Lloyd, Sioned
dc.contributor.author Lee, Jennifer
dc.contributor.author Hendriksz, Christian J.
dc.contributor.author Ramaswami, Uma
dc.date.accessioned 2020-08-12T13:37:09Z
dc.date.available 2020-08-12T13:37:09Z
dc.date.issued 2019-09
dc.description Supplementary Material 1: EQ-5D-5L domains walking ability results en_ZA
dc.description Supplementary Material 2: Patient questionnaires en_ZA
dc.description.abstract INTRODUCTION: Alpha-mannosidosis is an ultra-rare lysosomal storage disorder resulting from the deficient activity of lysosomal alpha-mannosidase. Alpha-mannosidosis presents as a highly heterogenous condition with large variations in symptom severity and disease progression rates. Quantitative and qualitative data for alphamannosidosis patients and their caregivers provide important insights into their daily experiences. METHODS: A survey of nine alpha-mannosidosis patients was carried out in the UK between August 2017 and January 2018. Patient demographics, health-related quality of life (HRQoL), and qualitative data from patients and carers relating to clinical characteristics and impact of the disease and treatment were analysed. RESULTS: At the time of survey completion, patient age ranged from 7 to 37 years. Five patients were described as ‘walking unassisted’, one as ‘walking with assistance’, one as ‘wheelchair-dependent’, and two as ‘severely immobile’. In addition to best supportive care, three patients had received haematopoietic stem cell transplantation (HSCT) and one had received velmanase alfa enzyme replacement therapy (ERT). Patient HRQoL results for the EQ-5D-5 L questionnaire and the Health Utilities Index-3 showed that patients with more severe ambulatory health states reported lower utility values than patients who were more mobile. Patients who received HSCT or ERT experienced improved HRQoL. Carer HRQoL results for the Hospital Anxiety and Depression Scale and Caregiver Strain Index demonstrated that carers experience high levels of stress and anxiety from their caregiving responsibilities. CONCLUSIONS: This survey confirmed the heterogeneity of alpha-mannosidosis and the large impact of the disease and treatment on patients, carers, and families. Early diagnosis and access to treatment offers the best chance of slowing the disease progression and may provide some relief to patients and carers. en_ZA
dc.description.department Paediatrics and Child Health en_ZA
dc.description.librarian pm2020 en_ZA
dc.description.sponsorship Chiesi Limited en_ZA
dc.description.uri http://www.elsevier.com/locate/ymgmr en_ZA
dc.identifier.citation Adam, J., Malone, R., Lloyd, S. et al. 2019, 'Disease progression of alpha-mannosidosis and impact on patients and carers – a UK natural history survey', Molecular Genetics and Metabolism Reports, vol. 20, art. 100480, pp. 1-9. en_ZA
dc.identifier.issn 2214-4269 (online)
dc.identifier.other 10.1016/j.ymgmr.2019.100480
dc.identifier.uri http://hdl.handle.net/2263/75668
dc.language.iso en en_ZA
dc.publisher Elsevier en_ZA
dc.rights © 2019 The Authors. Published by Elsevier Inc. This article is published under the CC BY license. en_ZA
dc.subject Alpha-mannosidosis en_ZA
dc.subject Lysosomal storage disorder en_ZA
dc.subject Velmanase alfa en_ZA
dc.subject Quality of life en_ZA
dc.subject Haematopoietic stem cell transplantation (HSCT) en_ZA
dc.subject Enzyme replacement therapy (ERT) en_ZA
dc.subject Health-related quality of life (HRQoL) en_ZA
dc.title Disease progression of alpha-mannosidosis and impact on patients and carers – a UK natural history survey en_ZA
dc.type Article en_ZA


Files in this item

This item appears in the following Collection(s)

Show simple item record